Rethorst, Chad D. http://orcid.org/0000-0002-8168-2829
Carmody, Thomas J.
Argenbright, Keith E.
Mayes, Taryn L.
Hamann, Heidi A.
Trivedi, Madhukar H.
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas (PP160121)
Article History
Received: 19 September 2022
Accepted: 13 March 2023
First Online: 20 April 2023
Declarations
:
: The study protocol was approved by the UT Southwestern IRB and participants signed an approved informed consent document prior to completing any study activities.
: Not applicable.
: Within the past 36 months, Dr. Trivedi has provided consulting services to ACADIA Pharmaceuticals, Allergan, Alkermes Inc., Alto Neuroscience Inc, Applied Clinical Intelligence, LLC, Axsome Therapeutics, Biogen MA Inc, Boegringer Ingelheim, Cerebral Inc., Circular Genomics Inc., Compass Pathfinder Limited, GH Research, GreenLight VitalSign6 Inc, Heading Health, Health Care Global Village, Janssen Pharmaceutical, Jazz Pharmaceutical, Legion Health, Lundbeck Research USA, Merck Sharp & Dohme Corp., Mind Medicine Inc., Myriad Neuroscience, Naki Health Ltd, Navitor, Neurocrine Biosciences Inc., Noema Pharma AG, Orexo US Inc., Otsuka America Pharmaceutical Inc, Perception Neuroscience Holdings, Pharmerit International, Policy Analysis Inc., Praxis Precision Medicines Inc, Rexahn Pharmaceuticals, Inc., SAGE Therapeutics, Signant Health, Sparian Biosciences, Titan Pharmaceuticals, Takeda Pharmaceuticals Inc, WebMD. He has received grant/research funding from NIMH, NIDA, NCATS, American Foundation for Suicide Prevention, Patient-Centered Outcomes Research Institute (PCORI), and Blue Cross Blue Shield of Texas. Additionally, he has received editorial compensation from Engage Health Media, and Oxford University Press. All other authors have no competing interests to report.